TYME Tyme Technologies Inc.

1.58
+0.02  (+1%)
Previous Close 1.56
Open 1.55
Price To Book 79
Market Cap 194,086,416
Shares 122,839,504
Volume 151,299
Short Ratio
Av. Daily Volume 410,067
Stock charts supplied by TradingView

NewsSee all news

  1. TYME Announces Fourth Quarter and Fiscal Year 2020 Financial and Operating Results

    TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer PanCAN enrolling patients in its Precision PromiseSM adaptive randomized Phase II/III

  2. Tyme Technologies to Present at Jefferies Virtual Healthcare Conference on June 3, 2020

    Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that leadership will participate at the Jefferies Virtual Healthcare Conference

  3. Health Economic Research Study Presented at ISPOR, and Published in the Journal Value in Health, Demonstrates Reduction in Total Cost of Care with Increased Use of New Medicines for Treatment of Patients with Pancreatic Cancer

    The study shows that for every additional $1 spent on innovative medicines for pancreatic cancer in 2016, there was a reduction in non-medicine spending of $8 to $9 This preliminary study reported that total medical

  4. TYME Announces Abstracts Selected for Presentation at the American Association for Cancer Research, AACR 2020

    Preclinical data suggests multiple mechanisms of action for SM-88, including an increase in reactive oxygen species, alterations in autophagy and immunomodulation Preclinical data for TYME-18, an intra-tumoral

  5. Tyme Technologies to Webcast Conference Call of Fourth Quarter and Fiscal Year 2020 Financial and Operating Results on May 20, 2020

    Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the Company will host a conference call and live webcast on Wednesday, May

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to complete enrolment by late-2020 to early-2021.
SM-88
Pancreatic cancer
Pivotal stage initiation announced September 25, 2019.
SM-88
Prostate cancer
Phase 2 dosing has commenced - January 16, 2020.
SM-88 - HopES
Ewing’s sarcoma

Latest News

  1. TYME Announces Fourth Quarter and Fiscal Year 2020 Financial and Operating Results

    TYME-88-Panc pivotal trial enrolling patients using oral SM-88 as a potential treatment for third-line pancreatic cancer PanCAN enrolling patients in its Precision PromiseSM adaptive randomized Phase II/III

  2. Tyme Technologies to Present at Jefferies Virtual Healthcare Conference on June 3, 2020

    Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that leadership will participate at the Jefferies Virtual Healthcare Conference

  3. Health Economic Research Study Presented at ISPOR, and Published in the Journal Value in Health, Demonstrates Reduction in Total Cost of Care with Increased Use of New Medicines for Treatment of Patients with Pancreatic Cancer

    The study shows that for every additional $1 spent on innovative medicines for pancreatic cancer in 2016, there was a reduction in non-medicine spending of $8 to $9 This preliminary study reported that total medical

  4. TYME Announces Abstracts Selected for Presentation at the American Association for Cancer Research, AACR 2020

    Preclinical data suggests multiple mechanisms of action for SM-88, including an increase in reactive oxygen species, alterations in autophagy and immunomodulation Preclinical data for TYME-18, an intra-tumoral

  5. Tyme Technologies to Webcast Conference Call of Fourth Quarter and Fiscal Year 2020 Financial and Operating Results on May 20, 2020

    Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the Company will host a conference call and live webcast on Wednesday, May

  6. Tyme Technologies to Present at the 2020 Cross-Border Healthcare Webinar Series

    Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 2020 Cross-Border Healthcare Webinar Series

  7. TYME Announces Third Quarter Fiscal 2020 Financial and Operating Results

    Strategic collaboration with Eagle Pharmaceuticals entitles TYME to receive up to a total of $40 million, which included $20 million upfront already received and $20 million in potential milestone payments.TYME-88-Panc

  8. Health Economic Research Study Demonstrates Increased Use of New Medicines in the Treatment of Patients with Pancreatic Cancer Reduces Total Cost of Care

    The study shows that for every additional $1 spent on innovative medicines for pancreatic cancer between 2009 to 2016, there was a reduction in non-medicine spending of $8 to $9  This preliminary study reported that cost

  9. TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas

    New oral approach aimed at disrupting cancer metabolism in high-risk sarcomas; 12,000 cases annually in U.S. aloneOral SM-88 represents a new approach designed to selectively disrupt protein synthesis in cancers with

  10. TYME Announces First Patient Dosed in TYME-88-Panc Pivotal Trial to Evaluate SM-88 as Oral Treatment for Patients with Metastatic Pancreatic Cancer

    Oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in cancers - demonstrated responses in 15 different cancer types across four separate studiesData presented at ESMO GI 2019 from

  11. Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer

    Collaboration leverages combined capabilities of Tyme Technologies and Eagle Pharmaceuticals to maximize potential of oral SM-88 by advancing pivotal trials and commercialization. TYME recently launched the

  12. Tyme Technologies to Present at the 2019 Cross-Border Healthcare Winter Summit in New York

    NEW YORK, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the

  13. TYME to Ring Nasdaq Opening Bell on November 27 to Honor All Stakeholders Committed to Finding a Cure for Patients with Pancreatic Cancer

    Pancreatic Cancer Expected to be the Second Leading Cause of Cancer-Related Death in the U.S. by 20201TYME's oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in cancers -

  14. Tyme Technologies to Present at the Evercore ISI HealthCONx Conference 2019

    NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the

  15. Tyme Technologies to Present at Jefferies 2019 London Healthcare Conference on November 20-21, 2019

    NEW YORK, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the

  16. TYME Presents Business Update and Reports Second Quarter Fiscal 2020 Financial and Operating Results

    Quarterly conference call today, November 4th, at 5 p.m. Eastern TimeUpdated Data From TYME-88-Panc PET Imaging and TYME-18 Preclinical Studies on Conference CallExpect Enrollment of Patients in the Pivotal Stage of

  17. LineaRx's iCTC Platform for Isolation of Circulating Tumor Cells Shows Superior Correlation over PSA as a Biomarker in Prostate Cancer Trial

    LineaRx Platform Used in Phase II trial in recurrent prostate cancer demonstrates the number of circulating tumor cells correlates more directly with disease status LineaRx, Inc., the majority-owned subsidiary of

  18. TYME Presented Updated Data at ESMO 2019 from SM-88 Phase II Prostate Cancer Study Demonstrating Encouraging Clinical Benefit in Patients with Recurrent Prostate Cancer

    Study results demonstrate that oral SM-88 may play a clinically meaningful role in postponing use of hormonal castration in prostate cancer patients with rising prostate-specific antigen (PSA):  More than 450,000 of

  19. TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic Cancer

    TYME launched its multicenter randomized controlled pivotal stage of TYME-88-Panc trial for use of SM-88 in patients with third-line pancreatic cancer based on these clinical outcomesSM-88 is an oral, investigational

  20. TYME Launches Pivotal Stage of TYME-88-PANC Trial to Evaluate SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic Cancer

    Oral SM-88 represents a new approach designed to selectively disrupt protein synthesis in cancers with demonstrated responses in 15 different cancer types across four separate studiesData presented at ESMO GI 2019 from

  21. Tyme Technologies to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019

    NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the

  22. TYME Presents Positive Circulating Tumor Cell Data from TYME-88-Panc Study in Patients with Advanced Pancreatic Cancer at AACR PANC 2019

    TYME-88-PANC Phase II study showed patients being treated with SM-88, who achieved at least an 80% reduction in circulating tumor cell burden, demonstrated a 60% decrease in risk of deathSM-88 is an oral, investigational

  23. Tyme Technologies to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright on September 9, 2019

    NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the